Corcept Therapeutics is trading 4.3% down at $91.23 in pre-market, pulling back after a volatile week that included several 4–6% swings.
- The decline appears to be an isolated reaction, as there are no fresh company-specific headlines, earnings, or FDA decisions tied to the move.
- The stock's downward trend contrasts with the broader risk-on tone currently observed in equity futures.